Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Lindsey Draper, MD serves as an Adjunct Instructor in the Roybal Laboratory within the Department of Medicine, Division of Hematology and Oncology at the University of California San Francisco School of Medicine. Her clinical practice focuses on the treatment of patients with recurrent ovarian cancer using systemic therapies including chemotherapy and immunotherapy, with a commitment to evaluating and offering clinical trial opportunities as part of individualized patient care. Dr. Draper completed her educational training with a B.S. in Biology from Juniata College (2010), an M.D. from the University of Maryland School of Medicine (2017), an Internal Medicine Residency at The Mount Sinai Hospital (2022), and is currently completing a Medical Oncology Fellowship at UCSF (2025-2027). Her research interests center on cancer immunotherapy, particularly T cell-based approaches for HPV-associated cancers and ovarian cancer. She investigates engineered T cell therapies targeting viral antigens in cervical and other HPV-related cancers, with a focus on overcoming treatment resistance and improving clinical outcomes through novel immunotherapeutic strategies. Her work bridges fundamental immunological mechanisms with clinical applications, emphasizing the translation of laboratory discoveries into patient treatments. Dr. Draper's publication record demonstrates consistent contributions to the field of cancer immunotherapy, with recent work focusing on TCR-engineered T cells for leukemia and HPV-associated malignancies. Her research trajectory shows increasing sophistication in T cell engineering approaches and a growing emphasis on addressing inflammatory responses and treatment resistance mechanisms. Parker Institute for Cancer Immunotherapy Early Career Research Award: Parker Scholar (2024) Gladstone-UCSF Institute of Genomic Immunology Symbiont Seed Grant for 'Antigen Discovery for Ovarian Cancer' (2024) Conquer Cancer Young Investigator Award, American Society of Clinical Oncology (2024) Women in Cancer Immunotherapy Network Leadership Institute Selected Participant, Society for Immunotherapy of Cancer (2024) Physician-Scientist Fellow, Chan Zuckerberg Biohub - San Francisco (2023-2025) As a physician-scientist, Dr. Draper maintains an active research program while providing clinical care, with particular emphasis on developing novel immunotherapies for gynecologic cancers. Her current fellowship at UCSF and multiple early-career awards indicate strong potential for continued contributions to the field of cancer immunotherapy. Dr. Draper works within the Roybal Laboratory at UCSF, which focuses on innovative approaches to cancer immunotherapy and T cell engineering. Her research intersects with multiple collaborative initiatives at UCSF, including the Parker Institute for Cancer Immunotherapy and the Gladstone-UCSF Institute of Genomic Immunology.
Vanessa Samouëlian, MD, PhD, serves as an Associate Clinical Professor in the Department of Obstetrics and Gynecology at the University of Montreal. Based at the Montreal University Hospital Center (CHUM), she specializes in gynecological oncology within the Gynecological Oncology division. Her institutional roles include leading Tumor Board meetings and serving as a service representative on CHUM's medical act evaluation committee and the University of Montreal externship committee. Her educational background includes: MD from University of Montpellier 1, France (1992-1998) Certificate of Clinical and Therapeutic Synthesis and Master's in Biological/Medical Sciences (1998) IUD in Colposcopy and Cervicovaginal Pathology (1999) DES in Gynecology-Obstetrics from University of Lille 2, France (2005) PhD from Biology-Health Doctoral School, University of Lille 2 (2007) Clinical Fellowship in Gynecology Oncology at CHUM (2009-2011) Dr. Samouëlian's research centers on gynecological malignancies with emphasis on cervical, endometrial, and vulvar cancers. She investigates molecular biomarkers for nodal metastasis, treatment outcomes in high-risk endometrial carcinoma, and surgical innovation including robotic techniques. Her work bridges clinical oncology, cancer pathology, and HPV vaccination strategies through national collaborations. Her 2015-2016 publications reveal a cohesive research trajectory focused on endometrial cancer through the Canadian High Risk Endometrial Cancer (CHREC) Consortium. Key themes include adjuvant therapy optimization, pathological pattern analysis (MELF invasion), and surgical training innovation using virtual reality simulation. These works demonstrate integration of clinical practice, molecular diagnostics, and surgical education within gynecologic oncology. Within CHUM's organizational structure, Dr. Samouëlian contributes to the Historical Assignment Team and Gynecological Oncology division. She co-developed the Contemporary Clinical Questions on HPV-Related Diseases and Vaccination booklet with Gynecologic Oncology Canada and Merck Canada, endorsed by major Canadian gynecological societies including the Society of Obstetricians and Gynaecologists of Canada.
Carina Mallard is Professor of Experimental Perinatal Brain Injury Research and Pro-Vice-Chancellor at the University of Gothenburg since July 2023, where she oversees research infrastructure and chairs the Research Board. She previously served as Deputy Vice-Chancellor (2021–2023) and Head of Core Facilities (2018–2021). Her academic career began with a Physiology degree from Lund University and a PhD in Pediatrics at the University of Auckland (1995), followed by a professorship appointment in 2006. Her research focuses on perinatal brain injury , particularly in premature infants , investigating neuroinflammatory mechanisms maternal dietary interventions neurovascular unit dynamics microglia activation long-term consequences of maternal obesity . Recent publications highlight her work on neonatal rodent models , transcriptomic profiling , and anti-inflammatory therapies . Key themes include RNA degradation , mitochondrial protection , and immune-neurovascular interactions . She has supervised 20 doctoral students since 2004 and collaborates internationally with institutions like King's College London. Contact details include two institutional emails and physical addresses across Gothenburg's biomedical campuses. Her leadership roles span research strategy, doctoral education, and EU-level scientific initiatives.
Christopher M. Overall is a Full Professor at the University of British Columbia in the Faculty of Dentistry, Department of Oral Biological and Medical Sciences . He is also a Principal Scientist at the Centre for Blood Research and holds associate memberships in UBC's Biochemistry & Molecular Biology , Obstetrics and Gynecology , and Bioinformatics Graduate Program departments. As a Canada Research Chair Laureate , he pioneered the field of degradomics to study proteases in vivo. B.D.S., University of Adelaide Ph.D., University of Toronto Postdoctoral Fellowship, UBC (with Nobel Laureate Michael Smith) Dr. Overall’s research focuses on protease proteomics and systems biology , particularly degradomics to analyze protease substrates in diseases like COVID-19 and immunodeficiency . His work on matrix metalloproteinases has revealed new therapeutic strategies for inflammatory diseases and cancer . His 15 most recent articles (2015–2008) demonstrate expertise in TAILS proteomics , protein terminomics , and protease network analysis with applications in arthritis , antiviral immunity , and precision medicine . Scientific Awards 2022 Helmut Holzer Award 2018 Royal Society of Canada Fellow 2014 Tony Pawson Canadian Proteomics Award 2013 IADR Distinguished Scientist Award Dr. Overall has mentored 61 trainees , including 9 full professors with department chairs, and received the UBC John McNeill Mentorship Award (2023). He leads the HUPO Chromosome-centric Human Proteome Project and consults for Genentech and Novartis .
Tim Q. Duong, Ph.D., is a Professor at Albert Einstein College of Medicine, affiliated with the Departments of Radiology, Biochemistry, Ophthalmology & Visual Sciences, and Neuroscience. His research focuses on medical imaging, MRI, image analysis, machine learning, and predictive modeling for studying diseases like COVID-19 , neurodegeneration (Alzheimer's, multiple sclerosis), brain injuries , and breast cancer . Develops AI-driven MRI techniques for early disease detection Investigates neuroplasticity in glaucoma and diabetic retinopathy Leads grants from NIH and National Eye Institute Research Trends : Recent publications emphasize AI integration in medical imaging, long-term effects of SARS-CoV-2, and advanced MRI applications for ocular and neurological disorders. Grants include multiple R01 awards for diabetic retinopathy and glaucoma studies. Training Opportunities : Actively recruits postdocs, research coordinators, and faculty. Offers research positions for graduate, medical, and high school students, including Regeneron Scholar programs. Labs & Teams : Leads the Duong Lab at Montefiore Medical Center, focusing on translational research for clinical imaging solutions.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Professor Carlo Pappone is a Full Professor of Cardiology at Vita-Salute San Raffaele University (since 2019) and Director of the Arrhythmology Department at IRCCS Policlinico San Donato Hospital (since 2015). He has held previous academic/clinical leadership roles at IRCCS San Raffaele Hospital (2000-2010), Villa Maria Cecilia Hospital (2010-2015), and University of Naples Federico II (1990-2000). With 212 publications in top journals like NEJM, JAMA, and Circulation, he has made significant contributions to cardiac arrhythmia research. Current Positions Vita-Salute San Raffaele University (2019-present): Full Professor of Cardiology IRCCS Policlinico San Donato Hospital (2015-present): Director of Arrhythmology Department Previous Roles University of Naples Federico II (1990-2000) University of Michigan Ann Harbor (1990-2000) IRCCS San Raffaele Hospital (2000-2010) Villa Maria Cecilia Hospital (2010-2015) Research Focus: Specializing in cardiovascular diseases, his work spans atrial fibrillation ablation techniques, Brugada syndrome pathogenesis, heart failure device therapy, and ion channel disorders. His H-index of 53 and 18,407 citations reflect his substantial academic impact. Notable Scientific Contributions Author of 44 patents Principal Investigator in 14 clinical trials (clinicaltrials.gov) Developed circumferential pulmonary vein ablation technique Innovator in biventricular pacing systems for heart failure Pioneered research on non-excitatory current for cardiac contractility Scientific Recognition Awarded as Elite Reviewer of JACC (2005) Editorial Board Member of 6 leading journals Reviewer for NEJM, JAMA, Lancet, and Nature Medicine Education Medical Doctorate: University of Naples Federico II
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Sachdev Sidhu is a Research Professor and Entrepreneur in Residence at the University of Waterloo. His research focuses on synthetic antibodies, protein engineering, and biotechnological applications. He leads efforts in developing novel therapeutic antibodies, engineered protein systems, and molecular tools for biomedical research. His work spans cancer therapy, viral infection countermeasures, and regenerative medicine. Sidhu is also involved in translational research, bridging academic discoveries with commercial applications through entrepreneurial ventures. Key research interests include synthetic antibody libraries, CAR T-cell engineering, ubiquitin-based therapeutics, and phage display technologies. He has contributed to advancements in targeted therapies for glioblastoma, leukemia, and ocular diseases. His team develops innovative methods for protein design, such as engineered ubiquitin variants and modular antibody architectures. Publications highlight breakthroughs in antibody-based treatments, including synNotch CAR T cells for glioblastoma and neutralizing antibodies against SARS-CoV-2. His work integrates structural biology, molecular biology, and computational approaches to address complex biomedical challenges. Sidhu collaborates with industry partners to advance technologies into clinical and commercial settings.
About Dr. Pegah Varamini Dr. Pegah Varamini is a Senior Lecturer in Pharmacy and Pharmacology at the Sydney Pharmacy School, University of Sydney, and a Casual Lecturer in Music Education at the Sydney Conservatorium of Music. She leads the Breast Cancer Targeting & Drug Delivery (BCTDD) Group, focusing on innovative drug delivery systems for Triple Negative Breast Cancer (TNBC). Her research integrates nanotechnology, targeted therapy, and translational medicine, supported by prestigious grants including the NBCF Fellowship (2016). Research & Education PharmD (Shiraz University of Medical Sciences) PhD in Pharmaceutical Sciences (University of Queensland) Second PhD in Music Education (University of Sydney Conservatorium of Music) Key Research Interests Her work centers on: Peptide-based targeting strategies using 'Trojan Horse' approaches for TNBC Development of nanomedicine for bone metastasis prevention Clinically relevant preclinical models for personalized breast cancer treatment Collaborations with international institutions (e.g., Harvard Medical School, University of Nantes) Teaching & Supervision Dr. Varamini coordinates Drug Design and Development (PCOL3012/3912) and supervises a multidisciplinary team of HDR students and postdoctoral researchers. Notable current students include PhD candidate Hany Ghaly and MPhil candidates Huimin Shao and Farhana Mollah. Awards & Recognition 2021 Equity Prize 2016 Top 25 Young Researchers of Australia and New Zealand 2018 Fresh Scientist of the Year Recipient of multiple grants totaling over AUD 2M Leadership & Outreach She co-chairs the Nanopharma cluster at Sydney Nano Institute and advises the WHO Global Breast Cancer Initiative. Her work has been featured in media outlets such as SBS Farsi News and NBCF publications.
Dr. Yildiz Bayazitoglu is the Harry S. Cameron Professor of Mechanical Engineering and Professor of Materials Science and NanoEngineering at Rice University since 1996. She joined Rice in 1977 and has held prior roles as an assistant professor at Middle East Technical University (1973–74) and a visiting assistant professor at the University of Houston (1975–76). Her education includes a B.S. from Middle East Technical University (1967), and M.S. and Ph.D. from the University of Michigan (1969 and 1974). Her research focuses on convective heat transfer with phase change , micro/nano-scale heat transfer , and radiation heat transfer . Key areas include thermal modeling of biomedical systems, containerless materials processing, and fuel cell design. She has pioneered work on nanofluids, interfacial thermal resistance, and radiation shielding for aerospace applications. Dr. Bayazitoglu has published over 200 technical papers and holds patents in thermal engineering. She authored two heat transfer textbooks and serves as Editor-in-Chief of the International Journal of Thermal Sciences . Her honors include ASME’s Heat Transfer Memorial Award, AAAS and AIAA Fellowships, and membership in the Turkish Academy of Sciences. Education: B.S., Middle East Technical University (1967) M.S., University of Michigan (1969) Ph.D., University of Michigan (1974) Leadership Roles: Former Vice-President of the International Center for Heat and Mass Transfer (2019–2021) Member of Turkish Academy of Sciences Energy Sources Committee (2017–2018) Her work bridges thermal engineering with biomedical, aerospace, and materials science applications, emphasizing practical solutions to complex thermal challenges.
Guoyao Wu is a Distinguished Professor of Animal Nutrition at Texas A&M University's College of Agriculture & Life Sciences, holding dual appointments in the Department of Animal Science and the Graduate Faculty of Nutrition. His expertise spans nutritional biochemistry, protein metabolism, and reproductive physiology. Dr. Wu earned his B.Sc. from South China Agricultural University, M.Sc. degrees from Beijing Agricultural University and the University of Alberta, and a Ph.D. from the University of Alberta, followed by postdoctoral training at McGill University and Memorial University of Newfoundland. His research focuses on amino acid and protein metabolism across molecular, cellular, and whole-animal levels, using models like cattle, pigs, and aquatic species. Key areas include placental nutrient transport, fetal programming, and the role of amino acids in mitigating conditions like sarcopenia and intrauterine growth restriction. He has pioneered studies on glycine, creatine, and citrulline supplementation in livestock and aquaculture. Dr. Wu has received over 15 prestigious awards from China, Canada, and the U.S., including the Thousand-People-Talent Award and Changjiang Scholar Award. He serves on editorial boards of journals like Amino Acids and Frontiers in Bioscience , and teaches graduate courses in protein metabolism. His work bridges basic science and applied nutrition, with implications for improving livestock productivity, human health, and aquaculture sustainability. Current projects address amino acid requirements of companion animals, microgravity effects on metabolism, and placental biology in ruminants.
